Table 3 Clinical outcomes
Inpatient stay | ||
|---|---|---|
Length of inpatient stay (days) | Mean (SD) | 11.7 (12.8) |
Median (Q1, Q3) | 8.0 (7.0, 12.0) | |
All-cause mortality rate | |||||
|---|---|---|---|---|---|
Variables | In-Hospital; n (%) | Follow-up; n (%) | Total 1-year; n (%) | ||
1-month | 6-month | 1-year | |||
N = 1346 | N = 1128 | N = 1033 | N = 951 | N = 1037 | |
Overall | |||||
Total mortality | 86 (6.4) | 29 (2.6) | 49 (4.7) | 67 (7.0) | 153 (14.8) |
AVR Group | |||||
Isolated AVR mortality | 38 (5.6) | 15 (2.6) | 25 (4.7) | 35 (7.3) | 73 (14.1) |
Non-isolated AVR | 48 (7.2) | 14 (2.6) | 24 (4.8) | 32 (6.8) | 80 (15.4) |
Diagnosis | |||||
Severe AS | 38 (8.2) | 10 (2.6) | 18 (5.0) | 26 (8.0) | 64 (17.6) |
Severe AR | 20 (5.8) | 9 (3.1) | 12 (4.4) | 15 (5.9) | 35 (12.7) |
Moderate AS | 5 (6.8) | 1 (1.6) | 4 (6.8) | 5 (9.4) | 10 (17.2) |
Moderate AR | 4 (3.4) | 1 (1.0) | 4 (4.4) | 5 (6.0) | 9 (10.3) |
Severe AS and Severe AR | 2 (4.2) | 1 (2.4) | 1 (2.7) | 2 (5.4) | 4 (10.3) |
Moderate AS and Moderate AR | 3 (4.4) | 0 | 1 (2.3) | 1 (2.6) | 4 (9.8) |
Severe AS, Moderate AR | 13 (6.7) | 6 (3.8) | 7 (4.8) | 11 (8.3) | 24 (16.4) |
Moderate AS, Severe AR | 1 (2.9) | 1 (3.4) | 2 (7.7) | 2 (8.0) | 3 (11.5) |
Mild AS | 0 | 0 | 0 | 0 | 0 |
Mild AR | 0 | 0 | 0 | 0 | 0 |
AS-Predominant vs. AR-Predominant vs. Similar-Severity Group | |||||
AS Predominant | 56 (7.6) | 17 (2.8) | 29 (5.1) | 42 (8.2) | 98 (17.2) |
AR Predominant | 25 (5.0) | 11 (2.6) | 18 (4.7) | 22 (6.1) | 47 (12.1) |
Similar Severity | 5 (4.3) | 1 (1.1) | 2 (2.5) | 3 (4.0) | 8 (10.0) |
AS-Predominant by Etiology | |||||
Bicuspid valve degeneration | 14 (4.7) | 3 (1.1) | 5 (2.0) | 6 (2.7) | 20 (8.5) |
Trileaflet valve degeneration | 33 (13.5) | 7 (3.5) | 15 (8.1) | 23 (13.4) | 56 (27.3) |
Rheumatic | 6 (4.2) | 4 (3.6) | 6 (6.0) | 9 (10.1) | 15 (15.8) |
Unicuspid | 0 | 0 | 0 | 0 | 0 |
Radiation | 0 | 0 | 0 | 0 | 0 |
Others | 3 (8.6) | 3 (10.0) | 3 (10.7) | 4 (16.0) | 7 (25.0) |
AR-Predominant by Etiology | |||||
Root dilatation | 5 (5.6) | 2 (2.6) | 5 (7.4) | 5 (7.8) | 10 (14.5) |
Rheumatic | 1 (1.4) | 0 | 2 (3.8) | 2 (3.9) | 3 (5.8) |
Infective endocarditis | 7 (10.9) | 2 (4.2) | 2 (4.7) | 3 (7.1) | 10 (20.4) |
Fused prolapse | 1 (1.8) | 1 (2.1) | 1 (2.2) | 1 (2.6) | 2 (5.0) |
Prolapsed RCC | 2 (4.7) | 0 | 2 (5.3) | 3 (8.3) | 5 (13.2) |
Trileaflet valve degeneration | 2 (8.0) | 1 (4.5) | 1 (5.3) | 2 (11.1) | 4 (20.0) |
Dissection | 3 (12.5) | 1 (5.0) | 1 (5.9) | 2 (11.8) | 5 (25.0) |
Prolapsed LCC | 1 (5.3) | 2 (11.8) | 2 (11.8) | 2 (12.5) | 3 (17.6) |
Bicuspid valve degeneration | 0 | 0 | 0 | 0 | 0 |
Prolapsed NCC | 0 | 0 | 0 | 0 | 0 |
Flail RCC | 1 (16.7) | 0 | 0 | 0 | 1 (33.3) |
SOV rupture | 0 | 0 | 0 | 0 | 0 |
Flail fused | 0 | 0 | 0 | 0 | 0 |
Flail NCC | 1 (33.3) | 0 | 0 | 0 | 1 (33.3) |
Quadricuspid | 0 | 0 | 0 | 0 | 0 |
Fused prolapse and root dilatation | 0 | 0 | 0 | 0 | 0 |
Others | 1 (1.9) | 2 (4.4) | 2 (4.7) | 2 (5.0) | 3 (7.3) |
Similar-Severity by Etiology | |||||
Rheumatic | 1 (2.2) | 1 (2.9) | 1 (3.3) | 2 (8.0) | 3 (11.5) |
Trileaflet valve degeneration | 2 (7.7) | 0 | 0 | 0 | 2 (10.0) |
Bicuspid valve degeneration | 1 (4.0) | 0 | 0 | 0 | 1 (5.9) |
Others | 1 (5.3) | 0 | 1 (6.3) | 1 (6.3) | 2 (11.8) |
AS Hemodynamic | |||||
HG-severe AS | 29 (6.0) | 11 (2.7) | 14 (3.8) | 23 (6.8) | 52 (14.2) |
PLF-LG severe AS | 7 (11.3) | 1 (2.0) | 3 (6.3) | 5 (11.6) | 12 (24.0) |
NF-LG severe AS | 8 (8.2) | 2 (2.4) | 4 (4.9) | 6 (7.9) | 14 (16.7) |
LF-LG severe AS | 8 (13.6) | 3 (6.7) | 5 (11.9) | 5 (13.5) | 13 (28.9) |
Moderate AS | 8 (5.2) | 2 (1.6) | 6 (5.2) | 7 (6.6) | 15 (13.2) |
Mild AS | 6 (6.7) | 1 (1.4) | 2 (3.2) | 2 (3.5) | 8 (12.7) |
Reverse area-gradient mismatch (moderate AS) | 1 (3.8) | 0 | 1 (5.3) | 1 (6.7) | 2 (12.5) |